Rosetta's microRNAs "very effective" in classifying renal tumours – study
This article was originally published in Clinica
Executive Summary
Israeli molecular diagnostics firm Rosetta Genomics has demonstrated in a study that its microRNA-based biomarkers could be used to help identify different types of renal tumours.